Clinical features, histology, and treatment outcomes of granular parakeratosis: a systematic review.
Journal
International journal of dermatology
ISSN: 1365-4632
Titre abrégé: Int J Dermatol
Pays: England
ID NLM: 0243704
Informations de publication
Date de publication:
Aug 2022
Aug 2022
Historique:
revised:
19
10
2021
received:
21
08
2021
accepted:
05
01
2022
pubmed:
31
1
2022
medline:
23
7
2022
entrez:
30
1
2022
Statut:
ppublish
Résumé
Granular parakeratosis is a rare disorder characterized by erythematous-brown hyperkeratotic papules and erythematous patches with scaling, occurring predominantly in the flexures and sites of occlusion. While the exact underlying pathogenesis remains unknown, there has been a wide variety of precipitating factors and treatment options reported in the literature. We systematically reviewed and identified precipitants of granular parakeratosis, as well as its clinical and histologic features and treatment outcomes. A comprehensive literature search was conducted using MEDLINE and Embase in March 2021. A total of 60 studies with 129 patients were included for analysis. An inciting factor was identified in 53.4%, the most common being topical agents including zinc oxide (17.1%), deodorant/antiperspirant (15.5%), and those containing benzalkonium chloride (7.0%). The majority presented with bilateral (68.2%) eruption of hyperkeratotic papules or erythematous patches and plaques, most frequently involving the axilla (56.5%). The prevailing histologic feature was retained keratohyalin granules within the stratum corneum in punch biopsy (97.2%) and curette (100%) specimens. Treatment options with reported success ranged from topical corticosteroids and systemic antibiotics to surgical interventions. We provide a systematic review of reported precipitants, clinical features, and treatment options that clinicians should consider when granular parakeratosis is considered.
Sections du résumé
BACKGROUND
BACKGROUND
Granular parakeratosis is a rare disorder characterized by erythematous-brown hyperkeratotic papules and erythematous patches with scaling, occurring predominantly in the flexures and sites of occlusion. While the exact underlying pathogenesis remains unknown, there has been a wide variety of precipitating factors and treatment options reported in the literature.
OBJECTIVE
OBJECTIVE
We systematically reviewed and identified precipitants of granular parakeratosis, as well as its clinical and histologic features and treatment outcomes.
METHOD
METHODS
A comprehensive literature search was conducted using MEDLINE and Embase in March 2021.
RESULTS
RESULTS
A total of 60 studies with 129 patients were included for analysis. An inciting factor was identified in 53.4%, the most common being topical agents including zinc oxide (17.1%), deodorant/antiperspirant (15.5%), and those containing benzalkonium chloride (7.0%). The majority presented with bilateral (68.2%) eruption of hyperkeratotic papules or erythematous patches and plaques, most frequently involving the axilla (56.5%). The prevailing histologic feature was retained keratohyalin granules within the stratum corneum in punch biopsy (97.2%) and curette (100%) specimens. Treatment options with reported success ranged from topical corticosteroids and systemic antibiotics to surgical interventions.
CONCLUSION
CONCLUSIONS
We provide a systematic review of reported precipitants, clinical features, and treatment options that clinicians should consider when granular parakeratosis is considered.
Identifiants
pubmed: 35094385
doi: 10.1111/ijd.16107
pmc: PMC9546368
doi:
Substances chimiques
Dermatologic Agents
0
Types de publication
Journal Article
Systematic Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
973-978Subventions
Organisme : Monash University
Informations de copyright
© 2022 The Authors. International Journal of Dermatology published by Wiley Periodicals LLC on behalf of the International Society of Dermatology.
Références
Br J Dermatol. 2014 Feb;170(2):479-80
pubmed: 24205979
Br J Dermatol. 2002 Nov;147(5):1003-6
pubmed: 12410715
J Am Acad Dermatol. 2008 May;58(5 Suppl 1):S84-7
pubmed: 18489055
Australas J Dermatol. 2017 Aug;58(3):e138-e140
pubmed: 27641714
Australas J Dermatol. 2020 May;61(2):159-160
pubmed: 31814105
J Am Acad Dermatol. 1997 Nov;37(5 Pt 1):789-90
pubmed: 9366832
J Am Acad Dermatol. 1991 Apr;24(4):541-4
pubmed: 2033126
J Cutan Pathol. 1999 Aug;26(7):339-52
pubmed: 10487291
Australas J Dermatol. 2020 Nov;61(4):377-378
pubmed: 32342991
J Am Acad Dermatol. 2005 May;52(5):863-7
pubmed: 15858479
Pediatr Dermatol. 2003 May-Jun;20(3):215-20
pubmed: 12787269
J Am Acad Dermatol. 1998 Sep;39(3):495-6
pubmed: 9738790
J Am Acad Dermatol. 1995 Aug;33(2 Pt 2):373-5
pubmed: 7615889
Pediatr Dermatol. 2002 Mar-Apr;19(2):146-7
pubmed: 11994180
Am J Dermatopathol. 2011 Jul;33(5):531-3
pubmed: 21587032
Pediatr Dermatol. 2015 May-Jun;32(3):392-6
pubmed: 25660113
Australas J Dermatol. 2019 Aug;60(3):254-256
pubmed: 30675899
Australas J Dermatol. 1998 Aug;39(3):186-7
pubmed: 9737049
J Am Acad Dermatol. 2004 May;50(5 Suppl):S93-6
pubmed: 15097939